Trial Profile
A randomized, open label, multicenter study evaluating the effects of octreotide acetate on circulating levels of chromogranin A in advanced prostate cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 07 Sep 2007 Status changed from recruiting to completed.
- 10 Nov 2005 New trial record.